ProShare Advisors
ATOS icon

ProShare Advisors’s Atossa Therapeutics ATOS Stock Holding History

ProShare Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,825
Closed -$18.4K – 2084
2025
Q1 		$18.4K Sell
1,825
-550
-23% -$6.68K ﹤0.01% 2044
2024
Q4 		$33.6K Buy
2,375
+782
+49% +$15.3K ﹤0.01% 2229
2024
Q3 		$36.3K Buy
+1,593
New +$32.2K ﹤0.01% 2011
2022
Q2 		– Sell
-1,462
Closed -$28K – 1818
2022
Q1 		$28K Sell
1,462
-242
-14% -$4.92K ﹤0.01% 2158
2021
Q4 		$41K Buy
1,704
+704
+70% +$25.8K ﹤0.01% 2302
2021
Q3 		$49K Sell
1,000
-1,023
-51% -$59.5K ﹤0.01% 1965
2021
Q2 		$192K Buy
+2,023
New +$107K ﹤0.01% 2156

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ProShare Advisors's ATOS Position: Q2 2025 in Review

ProShare Advisors sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 1,825 shares — an estimated $18.4K sold.

ProShare Advisors first reported a position in ATOS in Q2 2021 and held it in 7 quarters. The position peaked at $192K in Q2 2021. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • ProShare Advisors reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 1,825 Atossa Therapeutics shares in Q2 2025, an estimated $18.4K.
  • ProShare Advisors first reported a position in Atossa Therapeutics in Q2 2021 and held it in 7 quarters.
  • ProShare Advisors's Atossa Therapeutics position peaked at $192K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.